Segall Bryant & Hamill LLC Sells 9,313 Shares of Cytokinetics, Incorporated $CYTK

Segall Bryant & Hamill LLC decreased its position in Cytokinetics, Incorporated (NASDAQ:CYTK) by 4.9% in the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 180,200 shares of the biopharmaceutical company’s stock after selling 9,313 shares during the period. Segall Bryant & Hamill LLC’s holdings in Cytokinetics were worth $11,877,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. EverSource Wealth Advisors LLC increased its holdings in Cytokinetics by 723.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 766 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 673 shares during the period. Kemnay Advisory Services Inc. purchased a new stake in shares of Cytokinetics in the 4th quarter worth $27,000. Kestra Advisory Services LLC bought a new position in shares of Cytokinetics during the 4th quarter worth $29,000. Quarry LP bought a new position in shares of Cytokinetics during the 3rd quarter worth $30,000. Finally, TD Waterhouse Canada Inc. purchased a new position in shares of Cytokinetics during the fourth quarter valued at $32,000.

Insider Buying and Selling at Cytokinetics

In other news, EVP Andrew Callos sold 15,000 shares of Cytokinetics stock in a transaction on Monday, June 1st. The shares were sold at an average price of $74.08, for a total transaction of $1,111,200.00. Following the completion of the sale, the executive vice president directly owned 58,555 shares in the company, valued at approximately $4,337,754.40. The trade was a 20.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert I. Blum sold 7,500 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $84.92, for a total value of $636,900.00. Following the completion of the transaction, the chief executive officer directly owned 377,830 shares in the company, valued at approximately $32,085,323.60. The trade was a 1.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 118,679 shares of company stock worth $9,396,849. 2.60% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on CYTK. Wells Fargo & Company lifted their price objective on Cytokinetics from $95.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Mizuho raised their target price on shares of Cytokinetics from $100.00 to $118.00 and gave the company an “outperform” rating in a research report on Wednesday, June 24th. Wall Street Zen upgraded shares of Cytokinetics from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Truist Financial set a $106.00 price target on shares of Cytokinetics in a research report on Tuesday, May 5th. Finally, Stifel Nicolaus increased their price objective on shares of Cytokinetics from $98.00 to $108.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $99.90.

Cytokinetics Stock Performance

Cytokinetics stock opened at $77.13 on Monday. The stock has a market cap of $9.60 billion, a PE ratio of -11.28 and a beta of 0.42. The stock has a 50-day moving average of $78.75 and a two-hundred day moving average of $70.43. Cytokinetics, Incorporated has a one year low of $32.89 and a one year high of $88.31.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.67) earnings per share for the quarter, hitting analysts’ consensus estimates of ($1.67). The business had revenue of $19.36 million for the quarter, compared to analysts’ expectations of $8.52 million. Cytokinetics’s revenue was up 1112.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.36) EPS. As a group, sell-side analysts predict that Cytokinetics, Incorporated will post -6.2 EPS for the current fiscal year.

Cytokinetics News Roundup

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: UK approval and reimbursement support: The Medicines and Healthcare products Regulatory Agency authorized MYQORZO® (aficamten) across the United Kingdom for eligible adults with symptomatic obstructive hypertrophic cardiomyopathy. NICE also recommended aficamten for use in England and Wales, potentially expanding access to roughly 6,600 NHS patients. Commercial availability is expected later this year, creating a potential new revenue stream. Cytokinetics wins UK approval, NICE backing for heart disease drug
• Positive Sentiment: Encouraging clinical evidence: The UK decisions were supported by the phase 3 SEQUOIA-HCM trial, in which aficamten significantly improved peak oxygen uptake versus placebo. This strengthens the commercial case for the company’s lead cardiovascular drug. Cytokinetics announces MHRA authorization and NICE guidance
• Positive Sentiment: Generally favorable analyst view: Brokerages maintain a consensus “Moderate Buy” rating, with a reported average price target near $99.90, above recent trading levels. Some firms have set targets between $105 and $118. Cytokinetics receives Moderate Buy consensus rating
• Neutral Sentiment: Upcoming earnings catalyst: Analysts expect CYTK could exceed estimates in its upcoming second-quarter report. However, Cytokinetics remains unprofitable, and its prior quarter reported a loss of $1.67 per share despite revenue exceeding expectations. Cytokinetics earnings expectations
• Negative Sentiment: Continued insider selling: EVP Andrew Callos sold 14,000 shares worth approximately $1.12 million, reducing his ownership by 19.3%. The sale was made under a pre-arranged Rule 10b5-1 plan, limiting its value as a discretionary bearish signal, but it follows a broader pattern of insider sales without reported purchases in recent months. SEC insider trading filing

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.